(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
Figure out How to Track the Establishment of New 5G Pinnacles- Astonishing interstellar comet captured in new images by NASA Mars missions
- How Trump's marijuana executive order could change medical research landscape
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence
- Lightning on Jupiter could be up to 1 million times stronger than on Earth
- Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
- Whale stranded off Germany for days found stuck again
